IBS-C Drugs Market Report

Europe IBS-C Drugs Market Size, Status and Forecast 2014-2026

  • POSTDATE：Jun 25, 2020
  • PAGES：205
  • REPORT CODE：GMM582646
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The IBS-C Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 3.1% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe IBS-C Drugs Market Segmentations:

    By Player:

    • Sucampo Pharmaceuticals

    • Catalent Pharmaceuticals Solutions

    • Teva Pharmaceutical Industries

    • Bama-Geve, SLU

    • Astrazeneca Plc

    • The Menarini Group

    • Albireo Pharma Inc

    • Prometheus Laboratories Inc

    • Salix Pharmaceuticals Ltd

    • Synthetic Biologics, Inc

    • Yuhan Corp

    • Ironwood Pharmaceuticals, Inc

    • Novartis Pharma Ag

    • Ferring BV

    • Nestle

    • Ardelyx, Inc

    • Synergy Pharmaceuticals

    • Actavis Nordic A/S

    • Abbott Laboratories

    • Astellas Pharmaceuticals

    By Type:

    • Linaclotide

    • Lubiprostone

    • Osmotic Laxatives

    • Stimulant Laxatives

    • Others

    By End-User:

    • Hospital Pharmacies

    • Retail Pharmacies

    • Online Pharmacies

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of IBS-C Drugs Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe IBS-C Drugs Market Size and Growth Rate of Linaclotide from 2014 to 2026

    • 1.3.2 Europe IBS-C Drugs Market Size and Growth Rate of Lubiprostone from 2014 to 2026

    • 1.3.3 Europe IBS-C Drugs Market Size and Growth Rate of Osmotic Laxatives from 2014 to 2026

    • 1.3.4 Europe IBS-C Drugs Market Size and Growth Rate of Stimulant Laxatives from 2014 to 2026

    • 1.3.5 Europe IBS-C Drugs Market Size and Growth Rate of Others from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe IBS-C Drugs Market Size and Growth Rate of Hospital Pharmacies from 2014 to 2026

    • 1.4.2 Europe IBS-C Drugs Market Size and Growth Rate of Retail Pharmacies from 2014 to 2026

    • 1.4.3 Europe IBS-C Drugs Market Size and Growth Rate of Online Pharmacies from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of IBS-C Drugs Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of IBS-C Drugs by Major Types

      • 3.4.1 Market Size and Growth Rate of Linaclotide

      • 3.4.2 Market Size and Growth Rate of Lubiprostone

      • 3.4.3 Market Size and Growth Rate of Osmotic Laxatives

      • 3.4.4 Market Size and Growth Rate of Stimulant Laxatives

      • 3.4.5 Market Size and Growth Rate of Others

    4 Segmentation of IBS-C Drugs Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of IBS-C Drugs by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Hospital Pharmacies for Construction

      • 4.4.2 Market Size and Growth Rate of Retail Pharmacies for Construction

      • 4.4.3 Market Size and Growth Rate of Online Pharmacies for Construction

    5 Market Analysis by Major Regions

    • 5.1 Europe IBS-C Drugs Production Analysis by Top Regions

    • 5.2 Europe IBS-C Drugs Consumption Analysis by Top Regions

    • 5.3 Europe IBS-C Drugs Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany IBS-C Drugs Production, Import, Consumption and Export Analysis

      • 5.3.2 UK IBS-C Drugs Production, Import, Consumption and Export Analysis

      • 5.3.3 France IBS-C Drugs Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy IBS-C Drugs Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain IBS-C Drugs Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland IBS-C Drugs Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia IBS-C Drugs Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland IBS-C Drugs Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey IBS-C Drugs Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) IBS-C Drugs Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) IBS-C Drugs Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) IBS-C Drugs Production, Import, Consumption and Export Analysis

    6 Product Circulation of IBS-C Drugs Market among Top Countries

    • 6.1 Top 5 Export Countries in IBS-C Drugs Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in IBS-C Drugs Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in IBS-C Drugs Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in IBS-C Drugs Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in IBS-C Drugs Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in IBS-C Drugs Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany IBS-C Drugs Landscape Analysis

    • 7.1 Germany IBS-C Drugs Landscape Analysis by Major Types

    • 7.2 Germany IBS-C Drugs Landscape Analysis by Major End-Users

    8. UK IBS-C Drugs Landscape Analysis

    • 8.1 UK IBS-C Drugs Landscape Analysis by Major Types

    • 8.2 UK IBS-C Drugs Landscape Analysis by Major End-Users

    9. France IBS-C Drugs Landscape Analysis

    • 9.1 France IBS-C Drugs Landscape Analysis by Major Types

    • 9.2 France IBS-C Drugs Landscape Analysis by Major End-Users

    10. Italy IBS-C Drugs Landscape Analysis

    • 10.1 Italy IBS-C Drugs Landscape Analysis by Major Types

    • 10.2 Italy IBS-C Drugs Landscape Analysis by Major End-Users

    11. Spain IBS-C Drugs Landscape Analysis

    • 11.1 Spain IBS-C Drugs Landscape Analysis by Major Types

    • 11.2 Spain IBS-C Drugs Landscape Analysis by Major End-Users

    12. Poland IBS-C Drugs Landscape Analysis

    • 12.1 Poland IBS-C Drugs Landscape Analysis by Major Types

    • 12.2 Poland IBS-C Drugs Landscape Analysis by Major End-Users

    13. Russia IBS-C Drugs Landscape Analysis

    • 13.1 Russia IBS-C Drugs Landscape Analysis by Major Types

    • 13.2 Russia IBS-C Drugs Landscape Analysis by Major End-Users

    14. Switzerland IBS-C Drugs Landscape Analysis

    • 14.1 Switzerland IBS-C Drugs Landscape Analysis by Major Types

    • 14.2 Switzerland IBS-C Drugs Landscape Analysis by Major End-Users

    15. Turkey IBS-C Drugs Landscape Analysis

    • 15.1 Turkey IBS-C Drugs Landscape Analysis by Major Types

    • 15.2 Turkey IBS-C Drugs Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) IBS-C Drugs Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) IBS-C Drugs Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) IBS-C Drugs Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) IBS-C Drugs Landscape Analysis by Top Countries

      • 16.3.1 Denmark IBS-C Drugs Market Volume and Growth Rate

      • 16.3.2 Finland IBS-C Drugs Market Volume and Growth Rate

      • 16.3.3 Norway IBS-C Drugs Market Volume and Growth Rate

      • 16.3.4 Sweden IBS-C Drugs Market Volume and Growth Rate

      • 16.3.6 Iceland IBS-C Drugs Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) IBS-C Drugs Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) IBS-C Drugs Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) IBS-C Drugs Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) IBS-C Drugs Landscape Analysis by Top Countries

      • 17.3.1 Belgium IBS-C Drugs Market Volume and Growth Rate

      • 17.3.2 Netherlands IBS-C Drugs Market Volume and Growth Rate

      • 17.3.3 Luxembourg IBS-C Drugs Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) IBS-C Drugs Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) IBS-C Drugs Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) IBS-C Drugs Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) IBS-C Drugs Landscape Analysis by Top Countries

      • 18.3.1 Estonia IBS-C Drugs Market Volume and Growth Rate

      • 18.3.2 Latvia IBS-C Drugs Market Volume and Growth Rate

      • 18.3.3 Lithuania IBS-C Drugs Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Sucampo Pharmaceuticals

      • 19.1.1 Sucampo Pharmaceuticals Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Catalent Pharmaceuticals Solutions

      • 19.2.1 Catalent Pharmaceuticals Solutions Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Teva Pharmaceutical Industries

      • 19.3.1 Teva Pharmaceutical Industries Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Bama-Geve, SLU

      • 19.4.1 Bama-Geve, SLU Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Astrazeneca Plc

      • 19.5.1 Astrazeneca Plc Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 The Menarini Group

      • 19.6.1 The Menarini Group Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Albireo Pharma Inc

      • 19.7.1 Albireo Pharma Inc Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Prometheus Laboratories Inc

      • 19.8.1 Prometheus Laboratories Inc Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Salix Pharmaceuticals Ltd

      • 19.9.1 Salix Pharmaceuticals Ltd Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Synthetic Biologics, Inc

      • 19.10.1 Synthetic Biologics, Inc Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 Yuhan Corp

      • 19.11.1 Yuhan Corp Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 Ironwood Pharmaceuticals, Inc

      • 19.12.1 Ironwood Pharmaceuticals, Inc Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    • 19.13 Novartis Pharma Ag

      • 19.13.1 Novartis Pharma Ag Company Profile and Development Status

      • 19.13.2 Market Performance

      • 19.13.3 Product and Service Introduction

    • 19.14 Ferring BV

      • 19.14.1 Ferring BV Company Profile and Development Status

      • 19.14.2 Market Performance

      • 19.14.3 Product and Service Introduction

    • 19.15 Nestle

      • 19.15.1 Nestle Company Profile and Development Status

      • 19.15.2 Market Performance

      • 19.15.3 Product and Service Introduction

    • 19.16 Ardelyx, Inc

      • 19.16.1 Ardelyx, Inc Company Profile and Development Status

      • 19.16.2 Market Performance

      • 19.16.3 Product and Service Introduction

    • 19.17 Synergy Pharmaceuticals

      • 19.17.1 Synergy Pharmaceuticals Company Profile and Development Status

      • 19.17.2 Market Performance

      • 19.17.3 Product and Service Introduction

    • 19.18 Actavis Nordic A/S

      • 19.18.1 Actavis Nordic A/S Company Profile and Development Status

      • 19.18.2 Market Performance

      • 19.18.3 Product and Service Introduction

    • 19.19 Abbott Laboratories

      • 19.19.1 Abbott Laboratories Company Profile and Development Status

      • 19.19.2 Market Performance

      • 19.19.3 Product and Service Introduction

    • 19.20 Astellas Pharmaceuticals

      • 19.20.1 Astellas Pharmaceuticals Company Profile and Development Status

      • 19.20.2 Market Performance

      • 19.20.3 Product and Service Introduction

    The List of Tables and Figures (Totals 113 Figures and 171 Tables)

    • Figure Product Picture

    • Figure IBS-C Drugs Market Size and Growth Rate of Linaclotide Market, 2015 - 2026 (USD Million)

    • Figure IBS-C Drugs Market Size and Growth Rate of Lubiprostone Market, 2015 - 2026 (USD Million)

    • Figure IBS-C Drugs Market Size and Growth Rate of Osmotic Laxatives Market, 2015 - 2026 (USD Million)

    • Figure IBS-C Drugs Market Size and Growth Rate of Stimulant Laxatives Market, 2015 - 2026 (USD Million)

    • Figure IBS-C Drugs Market Size and Growth Rate of Others Market, 2015 - 2026 (USD Million)

    • Figure IBS-C Drugs Market Size and Growth Rate of Hospital Pharmacies from 2014 to 2026

    • Figure IBS-C Drugs Market Size and Growth Rate of Retail Pharmacies from 2014 to 2026

    • Figure IBS-C Drugs Market Size and Growth Rate of Online Pharmacies from 2014 to 2026

    • Figure Germany IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure UK IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure France IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Italy IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Spain IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Poland IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Russia IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Canada IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Finland IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Norway IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania IBS-C Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of IBS-C Drugs Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of IBS-C Drugs

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of IBS-C Drugs by Different Types from 2014 to 2026

    • Table Consumption Share of IBS-C Drugs by Different Types from 2014 to 2026

    • Figure IBS-C Drugs Market Size and Growth Rate of Linaclotide Market, 2015 - 2026 (USD Million)

    • Figure IBS-C Drugs Market Size and Growth Rate of Lubiprostone Market, 2015 - 2026 (USD Million)

    • Figure IBS-C Drugs Market Size and Growth Rate of Osmotic Laxatives Market, 2015 - 2026 (USD Million)

    • Figure IBS-C Drugs Market Size and Growth Rate of Stimulant Laxatives Market, 2015 - 2026 (USD Million)

    • Figure IBS-C Drugs Market Size and Growth Rate of Others Market, 2015 - 2026 (USD Million)

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of IBS-C Drugs by Different End-Users from 2014 to 2026

    • Table Consumption Share of IBS-C Drugs by Different End-Users from 2014 to 2026

    • Figure IBS-C Drugs Market Size and Growth Rate of Hospital Pharmacies from 2014 to 2026

    • Figure IBS-C Drugs Market Size and Growth Rate of Retail Pharmacies from 2014 to 2026

    • Figure IBS-C Drugs Market Size and Growth Rate of Online Pharmacies from 2014 to 2026

    • Table Europe IBS-C Drugs Production by Major Regions

    • Table Europe IBS-C Drugs Production Share by Major Regions

    • Figure Europe IBS-C Drugs Production Share by Major Countries and Regions in 2014

    • Table Europe IBS-C Drugs Consumption by Major Regions

    • Table Europe IBS-C Drugs Consumption Share by Major Regions

    • Table Germany IBS-C Drugs Production, Import, Consumption and Export Analysis

    • Table UK IBS-C Drugs Production, Import, Consumption and Export Analysis

    • Table France IBS-C Drugs Production, Import, Consumption and Export Analysis

    • Table Italy IBS-C Drugs Production, Import, Consumption and Export Analysis

    • Table Spain IBS-C Drugs Production, Import, Consumption and Export Analysis

    • Table Poland IBS-C Drugs Production, Import, Consumption and Export Analysis

    • Table Russia IBS-C Drugs Production, Import, Consumption and Export Analysis

    • Table Switzerland IBS-C Drugs Production, Import, Consumption and Export Analysis

    • Table Turkey IBS-C Drugs Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) IBS-C Drugs Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) IBS-C Drugs Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) IBS-C Drugs Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in IBS-C Drugs Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in IBS-C Drugs Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in IBS-C Drugs Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in IBS-C Drugs Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany IBS-C Drugs Consumption by Types from 2014 to 2026

    • Table Germany IBS-C Drugs Consumption Share by Types from 2014 to 2026

    • Table Germany IBS-C Drugs Consumption by End-Users from 2014 to 2026

    • Table Germany IBS-C Drugs Consumption Share by End-Users from 2014 to 2026

    • Table UK IBS-C Drugs Consumption by Types from 2014 to 2026

    • Table UK IBS-C Drugs Consumption Share by Types from 2014 to 2026

    • Table UK IBS-C Drugs Consumption by End-Users from 2014 to 2026

    • Table UK IBS-C Drugs Consumption Share by End-Users from 2014 to 2026

    • Table France IBS-C Drugs Consumption by Types from 2014 to 2026

    • Table France IBS-C Drugs Consumption Share by Types from 2014 to 2026

    • Table France IBS-C Drugs Consumption by End-Users from 2014 to 2026

    • Table France IBS-C Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Italy IBS-C Drugs Consumption by Types from 2014 to 2026

    • Table Italy IBS-C Drugs Consumption Share by Types from 2014 to 2026

    • Table Italy IBS-C Drugs Consumption by End-Users from 2014 to 2026

    • Table Italy IBS-C Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Spain IBS-C Drugs Consumption by Types from 2014 to 2026

    • Table Spain IBS-C Drugs Consumption Share by Types from 2014 to 2026

    • Table Spain IBS-C Drugs Consumption by End-Users from 2014 to 2026

    • Table Spain IBS-C Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Poland IBS-C Drugs Consumption by Types from 2014 to 2026

    • Table Poland IBS-C Drugs Consumption Share by Types from 2014 to 2026

    • Table Poland IBS-C Drugs Consumption by End-Users from 2014 to 2026

    • Table Poland IBS-C Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Russia IBS-C Drugs Consumption by Types from 2014 to 2026

    • Table Russia IBS-C Drugs Consumption Share by Types from 2014 to 2026

    • Table Russia IBS-C Drugs Consumption by End-Users from 2014 to 2026

    • Table Russia IBS-C Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland IBS-C Drugs Consumption by Types from 2014 to 2026

    • Table Switzerland IBS-C Drugs Consumption Share by Types from 2014 to 2026

    • Table Switzerland IBS-C Drugs Consumption by End-Users from 2014 to 2026

    • Table Switzerland IBS-C Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Turkey IBS-C Drugs Consumption by Types from 2014 to 2026

    • Table Turkey IBS-C Drugs Consumption Share by Types from 2014 to 2026

    • Table Turkey IBS-C Drugs Consumption by End-Users from 2014 to 2026

    • Table Turkey IBS-C Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) IBS-C Drugs Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) IBS-C Drugs Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) IBS-C Drugs Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) IBS-C Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) IBS-C Drugs Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) IBS-C Drugs Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark IBS-C Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland IBS-C Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway IBS-C Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden IBS-C Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland IBS-C Drugs Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) IBS-C Drugs Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) IBS-C Drugs Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) IBS-C Drugs Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) IBS-C Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) IBS-C Drugs Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) IBS-C Drugs Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium IBS-C Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands IBS-C Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg IBS-C Drugs Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) IBS-C Drugs Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) IBS-C Drugs Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) IBS-C Drugs Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) IBS-C Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) IBS-C Drugs Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) IBS-C Drugs Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia IBS-C Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia IBS-C Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries IBS-C Drugs Market Volume and Growth Rate from 2014 to 2026

    • Table Sucampo Pharmaceuticals Profiles

    • Table Sucampo Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Sucampo Pharmaceuticals Product benchmarking

    • Table Sucampo Pharmaceuticals Strategic initiatives

    • Table Sucampo Pharmaceuticals SWOT analysis

    • Table Catalent Pharmaceuticals Solutions Profiles

    • Table Catalent Pharmaceuticals Solutions Production, Value, Price, Gross Margin 2014-2019

    • Table Catalent Pharmaceuticals Solutions Product benchmarking

    • Table Catalent Pharmaceuticals Solutions Strategic initiatives

    • Table Catalent Pharmaceuticals Solutions SWOT analysis

    • Table Teva Pharmaceutical Industries Profiles

    • Table Teva Pharmaceutical Industries Production, Value, Price, Gross Margin 2014-2019

    • Table Teva Pharmaceutical Industries Product benchmarking

    • Table Teva Pharmaceutical Industries Strategic initiatives

    • Table Teva Pharmaceutical Industries SWOT analysis

    • Table Bama-Geve, SLU Profiles

    • Table Bama-Geve, SLU Production, Value, Price, Gross Margin 2014-2019

    • Table Bama-Geve, SLU Product benchmarking

    • Table Bama-Geve, SLU Strategic initiatives

    • Table Bama-Geve, SLU SWOT analysis

    • Table Astrazeneca Plc Profiles

    • Table Astrazeneca Plc Production, Value, Price, Gross Margin 2014-2019

    • Table Astrazeneca Plc Product benchmarking

    • Table Astrazeneca Plc Strategic initiatives

    • Table Astrazeneca Plc SWOT analysis

    • Table The Menarini Group Profiles

    • Table The Menarini Group Production, Value, Price, Gross Margin 2014-2019

    • Table The Menarini Group Product benchmarking

    • Table The Menarini Group Strategic initiatives

    • Table The Menarini Group SWOT analysis

    • Table Albireo Pharma Inc Profiles

    • Table Albireo Pharma Inc Production, Value, Price, Gross Margin 2014-2019

    • Table Albireo Pharma Inc Product benchmarking

    • Table Albireo Pharma Inc Strategic initiatives

    • Table Albireo Pharma Inc SWOT analysis

    • Table Prometheus Laboratories Inc Profiles

    • Table Prometheus Laboratories Inc Production, Value, Price, Gross Margin 2014-2019

    • Table Prometheus Laboratories Inc Product benchmarking

    • Table Prometheus Laboratories Inc Strategic initiatives

    • Table Prometheus Laboratories Inc SWOT analysis

    • Table Salix Pharmaceuticals Ltd Profiles

    • Table Salix Pharmaceuticals Ltd Production, Value, Price, Gross Margin 2014-2019

    • Table Salix Pharmaceuticals Ltd Product benchmarking

    • Table Salix Pharmaceuticals Ltd Strategic initiatives

    • Table Salix Pharmaceuticals Ltd SWOT analysis

    • Table Synthetic Biologics, Inc Profiles

    • Table Synthetic Biologics, Inc Production, Value, Price, Gross Margin 2014-2019

    • Table Synthetic Biologics, Inc Product benchmarking

    • Table Synthetic Biologics, Inc Strategic initiatives

    • Table Synthetic Biologics, Inc SWOT analysis

    • Table Yuhan Corp Profiles

    • Table Yuhan Corp Production, Value, Price, Gross Margin 2014-2019

    • Table Yuhan Corp Product benchmarking

    • Table Yuhan Corp Strategic initiatives

    • Table Yuhan Corp SWOT analysis

    • Table Ironwood Pharmaceuticals, Inc Profiles

    • Table Ironwood Pharmaceuticals, Inc Production, Value, Price, Gross Margin 2014-2019

    • Table Ironwood Pharmaceuticals, Inc Product benchmarking

    • Table Ironwood Pharmaceuticals, Inc Strategic initiatives

    • Table Ironwood Pharmaceuticals, Inc SWOT analysis

    • Table Novartis Pharma Ag Profiles

    • Table Novartis Pharma Ag Production, Value, Price, Gross Margin 2014-2019

    • Table Novartis Pharma Ag Product benchmarking

    • Table Novartis Pharma Ag Strategic initiatives

    • Table Novartis Pharma Ag SWOT analysis

    • Table Ferring BV Profiles

    • Table Ferring BV Production, Value, Price, Gross Margin 2014-2019

    • Table Ferring BV Product benchmarking

    • Table Ferring BV Strategic initiatives

    • Table Ferring BV SWOT analysis

    • Table Nestle Profiles

    • Table Nestle Production, Value, Price, Gross Margin 2014-2019

    • Table Nestle Product benchmarking

    • Table Nestle Strategic initiatives

    • Table Nestle SWOT analysis

    • Table Ardelyx, Inc Profiles

    • Table Ardelyx, Inc Production, Value, Price, Gross Margin 2014-2019

    • Table Ardelyx, Inc Product benchmarking

    • Table Ardelyx, Inc Strategic initiatives

    • Table Ardelyx, Inc SWOT analysis

    • Table Synergy Pharmaceuticals Profiles

    • Table Synergy Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Synergy Pharmaceuticals Product benchmarking

    • Table Synergy Pharmaceuticals Strategic initiatives

    • Table Synergy Pharmaceuticals SWOT analysis

    • Table Actavis Nordic A/S Profiles

    • Table Actavis Nordic A/S Production, Value, Price, Gross Margin 2014-2019

    • Table Actavis Nordic A/S Product benchmarking

    • Table Actavis Nordic A/S Strategic initiatives

    • Table Actavis Nordic A/S SWOT analysis

    • Table Abbott Laboratories Profiles

    • Table Abbott Laboratories Production, Value, Price, Gross Margin 2014-2019

    • Table Abbott Laboratories Product benchmarking

    • Table Abbott Laboratories Strategic initiatives

    • Table Abbott Laboratories SWOT analysis

    • Table Astellas Pharmaceuticals Profiles

    • Table Astellas Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Astellas Pharmaceuticals Product benchmarking

    • Table Astellas Pharmaceuticals Strategic initiatives

    • Table Astellas Pharmaceuticals SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US